The polymorphisms in the thyroid peroxidase gene were associated with the development of autoimmune thyroid disease and the serum levels of anti-thyroid peroxidase antibody

Tomari, Saki; Watanabe, Mikio; Inoue, Naohisa; Mizuma, Tomoyo; YAMANAKA, C.; Hidaka, Yoh; Iwatani, Yoshinori

doi:10.1507/endocrj.ej17-0191

Cited by 18 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results seemed to reflect that certain loci of above genes could be associated with AITDs Uyghur patients in [20,21]. In recent decades, a number of SNPs in the TPO gene have been genotyped and different loci showed different effect on ATIDs (both GD and HT, or respectively), which further clarified the important role of TPO played in the development of AITDs [21][22][23][24]. TG is a 660-kDa glycoprotein, which accounts for about 75%-80% of the total thyroid protein [25,26] and deserves to be a major AITDs susceptibility gene.…”

Section: Discussionmentioning

confidence: 75%

WITHDRAWN: Target region sequencing and gene polymorphism of Chinese Uyghur individuals with autoimmune thyroid diseases (AITDs)

Wang¹,

Wang²,

Guo³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

The autoimmune thyroid diseases (AITDs) can mainly involve complex interactions between environmental exposure and genetic susceptibility. At present, a majority of AITDs relative genes have been identified, but the results of different ethnic origin are inconsistent. Due to the special genetic characteristics of Uyghur and the unique environment of Xinjiang Uyghur Autonomous Region, the specific pathogenesis of AITDs Uyghur patients remains unknown. Our study was carried out in the group of 100 AITDs Uyghur patients (50 GD and 50 HT) and 50 Uyghur controls. DNA was extracted from peripheral blood leukocytes and region sequencing was performed to identify candidate genes and single nucleotide polymorphisms (SNPs). Following quality control, Chi-square and logistic regression tests were used for detecting the different frequencies of genotypes and alleles between cases and controls. The results of our analyses showed that the polymorphisms of TPO, TG, TSHR and PTPRC genes were associated with AITDs Uyghur patients; CD28, TPO, PTPRC and TG were related to GD; TG, STAT3 and IL2RA were connected with HT. In conclusion, our study may explore several SNPs associate with AITDs in Chinese Uyghur individuals.

show abstract

Section: Discussionmentioning

confidence: 75%

WITHDRAWN: Target region sequencing and gene polymorphism of Chinese Uyghur individuals with autoimmune thyroid diseases (AITDs)

Wang¹,

Wang²,

Guo³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Autoimmune thyroid diseases (AITDs), which primarily include Graves’ disease (GD) and Hashimoto’s thyroiditis (HT), are common organ-specific autoimmune diseases with varying severity and intractability [ 1 ]. AITDs are characterized by lymphocytic infiltration into the thyroid and the production of autoantibodies to thyroid-specific antigens, such as thyrotropin receptor (TSHR), thyroid peroxidase (TPO) and thyroglobulin (Tg) [ 2 – 4 ]. The presence of thyrotropin receptor (TSHR) autoantibody (TRAb) is used in the serological diagnosis of GD [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease

et al. 2021

View full text Add to dashboard Cite

Background Graves’ disease (GD) is one of the most common autoimmune thyroid diseases (AITDs) in humans, and thyrotropin receptor antibody (TRAb) is a characterized autoantibody in GD. The use of radioactive iodine therapy (RAI) for GD treatment is increasing. Objectives We studied the biological properties of TRAb and evaluated the effect of RAI therapy on TRAb in GD patients. Methods In total, 225 patients (22 onset GD patients without 131I therapy, 203 GD patients treated with 131I therapy) and 20 healthy individuals as normal controls were included in this study. Clinical assessments were performed, and we examined in vitro the biological properties of TRAb in the 22 onset GD patients and 20 controls as well as 84 GD patients with 131I therapy. Results Serum TRAb and thyroid peroxidase antibody (TPOAb) levels increased in the initial year of RAI treatment, and both antibodies decreased gradually after one year. After 5 years from radioiodine treatment, TRAb and TPOAb levels decreased in 88% and 65% of GD patients, respectively. The proportion of patients positive for thyroid-stimulatory antibody (TSAb) was significantly higher in the 7–12-month group, and thyroid-blocking antibody (TBAb) levels were elevated after one year in half of the patients who received 131I treatment. Conclusions Treatment of GD patients with radioiodine increased TPOAb and TRAb (their main biological properties were TSAbs) within the first year after therapy, and the main biological properties of elevated TRAb were TBAbs after 1 year.

show abstract

“…This similar prevalence of anti‐TPO may indicate that our study cohort has the same genetic risks to develop anti‐TPO compared with the random Dutch age‐matched women. Genetic studies indeed showed that single nucleotide polymorphisms in TPO and some other genes are associated with the presence of low‐ or high‐level anti‐TPO [34–36].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of red‐blood‐cell and non‐red‐blood‐cell‐targeted autoantibodies in alloimmunized postpartum women

et al. 2020

View full text Add to dashboard Cite

Background and Objectives Alloantibodies against red-blood-cell (RBC) antigens often coincide with alloantibodies against leucocytes and platelets and sometimes with autoantibodies towards various antigens. Chimerism may be one of the factors responsible for the combination of allo-and autoantibodies. Women with alloantibodies against RBC antigens causing haemolytic disease of the fetus and neonate may need to receive intrauterine transfusions. These transfusions increase not only maternal antibody formation but also fetomaternal bleeding and may enhance fetal chimerism. We determined the prevalence of and risk factors for autoantibodies against some common clinical target antigens, in alloimmunized women after IUT. Materials and Methods We tested for autoantibodies against RBC, anti-thyroid peroxidase, anti-extractable nuclear antigens, anti-cyclic citrullinated proteins and anti-tissue transglutaminase. Women with and without autoantibodies were compared for age; number of RBC alloantibodies, pregnancies and IUTs, and other factors that may play a role in immunization. Results Non-RBC-targeted autoantibodies were present in 40 of 258 tested women (15Á5%, with 90% anti-TPO specificity), comparable to the prevalence reported in healthy Dutch women of these ages. Surprisingly, compared with women who had a single RBC alloantibody, a significantly higher proportion of women with multiple RBC alloantibodies had autoantibodies (5Á3% and 18Á4%, respectively; odds ratio 4Á06, 95% CI: 1Á20-13Á7). Other characteristics of women with and without autoantibodies were not different. Conclusion Multiple RBC alloantibodies after extensive allogeneic exposure during pregnancy and presumed increased fetomaternal chimerism are not associated with (selected) autoantibodies. Lack of allo-RBC multi-responsiveness seems associated with decreased auto(-TPO) antibody formation.

show abstract

The polymorphisms in the thyroid peroxidase gene were associated with the development of autoimmune thyroid disease and the serum levels of anti-thyroid peroxidase antibody

Cited by 18 publications

References 16 publications

WITHDRAWN: Target region sequencing and gene polymorphism of Chinese Uyghur individuals with autoimmune thyroid diseases (AITDs)

WITHDRAWN: Target region sequencing and gene polymorphism of Chinese Uyghur individuals with autoimmune thyroid diseases (AITDs)

The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease

Prevalence of red‐blood‐cell and non‐red‐blood‐cell‐targeted autoantibodies in alloimmunized postpartum women

Contact Info

Product

Resources

About